Abstract
Heparin-induced thrombocytopenia (HIT) is not uncommon in clinical practice, and may go unrecognized in a substantial number of patients. The pathophysiology of HIT has only recently been better understood. Patients with HIT may require anticoagulation for thrombotic complications that result in severe morbidity and mortality. These patients may also require anticoagulation for acute coronary syndromes (ACS), or during percutaneous coronary interventions (PCIs). The direct thrombin inhibitors are currently the anticoagulant of choice in HIT patients with ACS or those undergoing PCI, based on data from several large clinical trials in ACS and PCI populations, and data from smaller experiences, specifically in patients with HIT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
